Time to open the blood-brain barrier gate for biologics?

Future Neurology

Volumn 9, Issue 3, 2014, Pages 243-245

  Freskgård, Per Ola ^a   Niewoehner, Jens ^b   Urich, Eduard ^a  

^a F Hoffmann La Roche   (Switzerland)

^b Pharma Research and Early Development   (Germany)

Author keywords

biologic; blood brain barrier; brain disorder; receptor mediated transport

Indexed keywords

ANTIBODY; BIOLOGICAL PRODUCT; FC RECEPTOR; INSULIN RECEPTOR;

ANTIBODY ENGINEERING; BLOOD BRAIN BARRIER; DIMERIZATION; DRUG PENETRATION; DRUG TRANSPORT; INTRACELLULAR TRANSPORT; OLIGOMERIZATION; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

EID: 84901945935     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.14.15     Document Type: Review

References (18)

1. Ehrlich P. [Oxygen Necessity of the Organism. A Colourful Analytical Study.] August Hirschwald, Berlin, Germany (1885).
2. Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr. Opin. Pharmacol. 12, 615-622 (2012).
3. Pardridge WM. Receptor-mediated peptide-transport through the blood-brain-barrier. Endocr. Rev. 7, 314-330 (1986).
4. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl Acad. Sci. USA 88, 4771-4775 (1991). (Pubitemid 21914624)
5. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 6, 494-500 (2006). (Pubitemid 44348531)
6. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584-1596 (2013).
7. Strohl W, Strohl L. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. Woodhead Publishing Series in Biomedicine, Cambridge, UK (2012).
8. Naik P, Cucullo L. In vitro blood-brain barrier models: current and perspective technologies. J. Pharm. Sci. 101, 1337-1354 (2012).
9. Lippmann ES, Azarin SM, Kay JE et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30, 783-791 (2012).
10. Urich E, Lazic SE, Molnos J, Wells I, Freskgard PO. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE 7 (5), e38149 (2012).
11. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24, 1193-1204 (2004). (Pubitemid 39482480)
12. Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 80, 32-39 (2011).
13. Niewoehner J, Bohrmann B, Collin L et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49-60 (2014).
14. Bien-Ly N, Yu YJ, Bumbaca D et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211, 233-244 (2014).
15. Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 1, 983-993 (2009).
16. Couch JA, Yu YJ, Zhang Y et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. (183), 183ra57 (2013).
17. Ohshima-Hosoyama S, Simmons HA, Goecks N et al. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE 7(6), e39036 (2012).
18. Zhang, MC, Riedel H. Insulin receptor kinase-independent signaling via tyrosine phosphorylation of phosphatase PHLPP1. J. Cell. Biochem. 107, 65-75 (2009).